It is a novel methodology primarily employed for "skin tightening," which involves compacting and reshaping the skin. Additionally, it addresses any excess fat that may be present in the treated area, promoting its removal.
The procedure is minimally invasive and is executed using particularly fine optical laser fibers that are inserted directly beneath the skin, without cuts or incisions. The laser fiber heats the soft tissues it encounters, elevating the subcutaneous structures to a high temperature: adipose lobules are partially dissolved, blood vessels coagulate, and fibrous tissues contract and remodel.
Methodology and Protocols
The areas typically treated using this approach encompass those of the face, neck, and body where skin laxity and excess adiposity are present.
One or two sessions per year are envisaged, contingent upon the extent of the area and the tissue's structure. The therapy is minimally invasive and necessitates the use of small quantities of local anesthetic. Following the initial application, a moderate and localized edema may develop, which, upon initial examination, might not manifest the skin tightening or reduction in adipose mass, traits observable once the edema has subsided. The final result ought to be appraised no earlier than three months.
Risks and Contraindications
The treatment is safe, yet individual responses vary, making it impossible to quantify in advance the extent and duration of the outcome, nor the number of sessions required to achieve it.
During and following the procedure, aesthetic and/or functional discomfort of varying durations may arise (redness, swelling, bruising, hematoma, ulceration, abrasion, pain, "popcorn" effect, etc.). Other issues are exceedingly rare (skin burns of varying degrees due to an individual response, potential alterations in sensitivity or temporary nerve damage).
The following individuals should not undergo treatment: those with skin wounds, abrasions, or localized skin conditions in the area that needs to be treated; individuals with spastic paralysis; individuals with thrombosis and/or thrombophlebitis; individuals with serious health conditions; and pregnant women.